

13 October 2009

## Notification of letrozole Tender decision

PHARMAC is pleased to announce its decision to award the Tender for letrozole 2.5 mg tablet to Douglas Pharmaceuticals Ltd, as a result of the Invitation to Tender dated 23 December 2008.

### *Details of this decision*

- The Letara brand of letrozole 2.5 mg tablet will be listed from 1 February 2010 in Section B and in Part II of Section H of the Pharmaceutical Schedule, at the following price and subsidy (ex-manufacturer, excluding GST):

Pharmaceutical	Brand	Form and Strength	Pack Size	Price and subsidy
Letrozole	Letara	Tab 2.5 mg	30	\$26.55

- Letara will be fully funded without restriction;
- Letara will have Sole Supply Status from 1 July 2010 to 30 June 2012 and Hospital Supply Status from 1 April 2010 to 30 June 2012, with a 1% discretionary variance limit; and
- the subsidy for the incumbent brand of letrozole (Femara, supplied by Novartis) will be reduced to the level of Letara through the application of reference pricing from 1 April 2010, and Femara will be delisted from the Pharmaceutical Schedule on 1 July 2010.

A summary of this decision will also be included in the December Tender Notification, in line with the usual tender notification timelines.

### **More information**

If you have any queries about this change please contact the PHARMAC helpline on 0800 66 00 50 (9 am to 5 pm weekdays).